ZTS logo

ZOETIS INC

ZTSNYSE
πŸ† #380 by market capEarnings Nov 5US Equity
$77.78β–Ό $0.44 (βˆ’0.56%)
Market closed Β· at close
πŸ””
Track ZTS
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 0.6%
7dβ–Ό 5.1%
14dβ–Ό 0.9%
30dβ–² 10.6%
ytdβ–Ό 38.2%
1yβ–Ό 45.9%
🏦Market Cap
$32.14B
Mid Cap
πŸ“ˆRevenue Growth (YoY)
2.3%
Slowing
πŸ“ŠGross Margin
70.9%
High
πŸ’΅FCF Margin
24.9%
Strong
βš–οΈP/S Ratio
3.4x
Fair
Otter Score
80
Strong

Trading Snapshot

Day Range
$77.06 – $78.50
52-Week Range
$68.77 – $146.11
Volume (shares)
159,108
Avg Volume (shares)
β€”
Shares Outstanding
413.2M
Next Earnings
2026-11-05

Fundamentals Snapshot

Annual Revenue
$9.47B
Last Q Revenue
$2.47B
P/E Ratio
12.8
P/S Ratio
3.4x
EPS (TTM)
$6.26
Dividend Yield
2.69%
Dilution (1yr)
βˆ’2.8%
ZTS logo

ZOETIS INC

ZTS
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$9.5Bβ–² +2.3% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
70.5%β–² +2.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$3.6Bβ–² +6.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$2.3Bβ–Ό βˆ’0.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
438.6Mβ–Ό βˆ’2.8% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$7.2Bβ–Ό βˆ’$2.4B YoY
StockOtter Β· stockotter.space

About ZOETIS INC

Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Strong
80/100

Analyst Ratings

β“˜
Consensus
Buy
23 analysts
Strong Buy3
Buy8
Hold12
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.